{"url":"https://lda.senate.gov/api/v1/filings/b9c37717-8923-4f3d-8249-c0ec59bed8b5/","filing_uuid":"b9c37717-8923-4f3d-8249-c0ec59bed8b5","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2021,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/b9c37717-8923-4f3d-8249-c0ec59bed8b5/print/","filing_document_content_type":"text/html","income":null,"expenses":"1800000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"William J. Schuyler","dt_posted":"2021-04-20T23:59:54.460000-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1050 K STREET, NW, #800","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":16293,"url":"https://lda.senate.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-01-30T14:26:09.773696-05:00"},"client":{"id":121722,"url":"https://lda.senate.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines\nH.R. 387: Vaccinate More Americans Act of 2021 - Provisions related to COVID-19 vaccines\nH.R. 467: Protecting Patient Access to Lifesaving COVID-19 Drugs Act of 2021 - Provisions related to COVID-19 treatments\nH.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to drug pricing and COVID-19 vaccines and treatments\nH.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process\nH.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation\nH.R. 853: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B drug discount program\nH.R. 1391: Taxpayer Research and Coronavirus Knowledge Act of 2021 - Provisions related to COVID-19 health research\nH.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products\nH.R. 2181: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals. - Provisions related to prescription drug importation\nH.R. 2347: To amend title XIX of the Social Security Act to ensure adequate access to vaccines under the Medicaid program and the Vaccines for Children program, and for other purposes. - Provisions related to COVID-19 vaccines\nS. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process\nS. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products\nS. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation\nS. 562: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions - Provisions related to citizen petitions\nS. 670: To amend the Federal Food, Drug, and Cosmetic Act to accelerate development of therapies across the spectrum of rare diseases and conditions and facilitate patient access to such therapies, and for other purposes. - Provisions related to FDA policy and health research\nS. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. - Provisions related to 340B drug discount program\nS. 898: A bill to require reporting regarding certain drug price increases, and for other purposes. - Provisions related to prescription drug pricing transparency\nS. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages\nS. 920: To amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals - Provisions related to prescription drug importation\nHHS PREP Act declaration relating to COVID-19\nDrug cost and pricing policy issues\nDrug importation policy issues\nExpanded access policy issues\nSupply chain policy issues\nReal world evidence policy issues\nRegenerative medicine policy issues\nAntimicrobial resistance (AMR) policy issues\nFDA modernization policy issues\n340B drug discount program policy issues\nPatient assistance program policy issues\nForeign manufacturing policy issues\nBiosimilar approval and reimbursement policy issues\nDrug shortages policy issues\nRegulatory efficiencies policy issues\nCOVID-19 policy issues\nDefense Production Act (DPA) policy issues\nFinal Rule; Importation of Prescription Drugs\nExecutive Order 14017, Americas Supply Chains (February 24, 2021)\nExecutive Order 13948, Lowering Drug Prices by Putting America First (September 13, 2020)\nInterim Final Rule with comment period; Most Favored Nation (MFN) Model\nExecutive Order 13944, Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (August 6, 2020)\nBuy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients\nNomination of HHS Secretary Xavier Becerra\nNominaton of USTR Katherine Tai\nNomination of OMB Deputy Director Shalanda Young\nNomination of CMS Administrator Chiquita Brooks-LaSure","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4722,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"J","last_name":"SCHUYLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65109,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":"J","last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138759,"prefix":"mr","prefix_display":"MR.","first_name":"ALEC","nickname":null,"middle_name":"RUBIO","last_name":"HINOJOSA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66514,"prefix":null,"prefix_display":null,"first_name":"PHILIP","nickname":null,"middle_name":"M","last_name":"THEVENET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71860,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79228,"prefix":null,"prefix_display":null,"first_name":"CURTIS","nickname":null,"middle_name":"E","last_name":"RHYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":99512,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"BREWER","suffix":null,"suffix_display":null},"covered_position":"Legislative Assistant, Cong. Max Cleland, Jan 1999 - Dec 1999","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1319: American Rescue Plan Act of 2021\nCARES Act, Pub. L. 116-136","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4722,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"J","last_name":"SCHUYLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65109,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":"J","last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66514,"prefix":null,"prefix_display":null,"first_name":"PHILIP","nickname":null,"middle_name":"M","last_name":"THEVENET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138759,"prefix":"mr","prefix_display":"MR.","first_name":"ALEC","nickname":null,"middle_name":"RUBIO","last_name":"HINOJOSA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71860,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79228,"prefix":null,"prefix_display":null,"first_name":"CURTIS","nickname":null,"middle_name":"E","last_name":"RHYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 3: Lower Drug Costs Now Act of 2019  [116th Congress]\nH.R. 19: Lower Costs, More Cures Act of 2019  [116th Congress]\nH.R. 1167: Advancing Enrollment and Reducing Drug Costs Act of 2021 - Provisions related to Part D\nH.R. 1227: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference\nH.R. 1976: To establish an improved Medicare for All national health insurance program - Provisions related to Part D and non-interference\nH.R. 2010: To amend the Patient Protection and Affordable Care Act to establish a public health insurance option - Provisions related to Part D and non-interference\nH.R. 2071: To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries - Provisions related to Part D and non-interference\nH.R. 2139: To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes - Provisions related to Part D and non-interference\nH.R. 2170: To amend title XIX of the Social Security Act to improve access to adult vaccines under Medicaid - Provisions related to COVID-19 vaccines\nS. 386: Medicare-X Choice Act of 2021 - Provisions related to Part D and non-interference\nS. 833: A bill to amend XVIII of the Social Security Act to allow the Secretary of Health and Human Services to negotiate fair prescription drug prices under part D of the Medicare program - Provisions related to Part D and non-interference\nS. 983: A bill to amend the Patient Protection and Affordable Care Act to establish a public health insurance option, and for other purposes - Provisions related to Part D and non-interference\nDepartment of Health and Human Services (HHS) drug policy issues and regulatory policy issues\nPart D redesign and policy issues including non-interference and rebates policy issues\nPart B policy issues\nDrug cost and pricing policy issues\nTransparency policy issues\nAlternative payment models policy issues\nValue-based purchasing arrangements policy issues\nAnti-Kickback Statute policy issues\nCenter for Medicare and Medicaid Innovation (CMMI) policy issues\nMedicaid rebates and waiver policy issues\nMedicare prescription drug payments cards and related policy issues\nFinal Rule; Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2021; Notice Requirement for Non-Federal Governmental Plans\nCalendar Year (CY) 2022 Request for Applications (RFA) for the Part D payment Modernization Model - Part D Formulary Flexibility\nFinal Rule; Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements\nFinal Rule; Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138759,"prefix":"mr","prefix_display":"MR.","first_name":"ALEC","nickname":null,"middle_name":"RUBIO","last_name":"HINOJOSA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":4722,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"J","last_name":"SCHUYLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65109,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":"J","last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66514,"prefix":null,"prefix_display":null,"first_name":"PHILIP","nickname":null,"middle_name":"M","last_name":"THEVENET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71860,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79228,"prefix":null,"prefix_display":null,"first_name":"CURTIS","nickname":null,"middle_name":"E","last_name":"RHYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"H.R. 171: Resilient Manufacturing Task Force Act of 2021 - Provisions related to medical supply chains and domesic manufacturing\nH.R. 1024: COVID-19 Supply Chain Resiliency Act of 2021 - Provisions related to medical supply chains\nH.R. 1186: Supply Chain Security and Pharmaceutical Authentication Act of 2021 - Provisions related to medical supply chains\nH.R. 2279: To establish the Office of Manufacturing and Industrial Innovation Policy and strategic national manufacturing policy for the United States, to provide manufacturing and industrial perspective and advice to the President, to provide for a comprehensive survey and cross administration management of efforts to ensure global leadership in manufacturing critical to the long-term economic health and national security of the United States, and for other purposes. - Provisions related to medical supply chains\nS. 298: Pharmacy Benefit Manager Accountability Study Act of 20201 - To require the Government Accountability Office to study the role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes\nTrade Agreements including USMCA and related policy issues\nBiopharmaceutical innovation policy issues\nInternational intellectual property and market access policy issues\nPricing and reimbursement policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138759,"prefix":"mr","prefix_display":"MR.","first_name":"ALEC","nickname":null,"middle_name":"RUBIO","last_name":"HINOJOSA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":4722,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"J","last_name":"SCHUYLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":56710,"prefix":null,"prefix_display":null,"first_name":"SHIRA","nickname":null,"middle_name":null,"last_name":"KILCOYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65109,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":"J","last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66514,"prefix":null,"prefix_display":null,"first_name":"PHILIP","nickname":null,"middle_name":"M","last_name":"THEVENET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71860,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79228,"prefix":null,"prefix_display":null,"first_name":"CURTIS","nickname":null,"middle_name":"E","last_name":"RHYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"H.R. 153: Protecting Consumer Access to Generic Drugs Act of 2021 - Provisions related to patent settlements\nH.R. 597: Pandemic Treatment Access and Affordability Act of 2021 - Provisions related to intellectual property\nH.R. 728: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights\nH.R. 1629: To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes - Provisions related to FDA policy and orphan drugs\nH.R. 1857: To amend the Federal Food, Drug, and Cosmetic Act to clarify the meaning of a new chemical entity - Provisions related to FDA policy and exclusivity\nH.R. 2148: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and march-in rights\nS. 187: Pandemic Emergency Manufacturing Act of 2021 - Provisions related to intellectual property and march-in rights\nS. 250: Fairness in Orphan Drug Exclusivity Act - Provisions related to FDA policy and orphan drugs\nS. 415: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the scope of new chemical exclusivity - Provisions related to FDA policy and exclusivity\nS. 908: To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries - Provisions related to prescription drug pricing and intellectual property\nS. 917: A bill to allow for expedited approval of generic prescription drugs and temporary importation of prescription drugs in the case of marginally competitive drug markets and drug shortages\nBiopharmaceutical innovation and patent policy issues\nBayh-Dole march-in rights policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":4722,"prefix":"mr","prefix_display":"MR.","first_name":"WILLIAM","nickname":null,"middle_name":"J","last_name":"SCHUYLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138759,"prefix":"mr","prefix_display":"MR.","first_name":"ALEC","nickname":null,"middle_name":"RUBIO","last_name":"HINOJOSA","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65109,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":"J","last_name":"CALVO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66514,"prefix":null,"prefix_display":null,"first_name":"PHILIP","nickname":null,"middle_name":"M","last_name":"THEVENET","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71860,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"DALE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":79228,"prefix":null,"prefix_display":null,"first_name":"CURTIS","nickname":null,"middle_name":"E","last_name":"RHYNE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}